Article | Published:

Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells

Nature Medicine volume 18, pages 12481253 (2012) | Download Citation

Abstract

Interleukin-9 (IL-9) is a T cell cytokine that acts through a γC-family receptor on target cells and is associated with inflammation and allergy. We determined that T cells from mice deficient in the T helper type 17 (TH17) pathway genes encoding retinoid-related orphan receptor γ (ROR-γ) and IL-23 receptor (IL-23R) produced abundant IL-9, and we found substantial growth inhibition of B16F10 melanoma in these mice. IL-9–blocking antibodies reversed this tumor growth inhibition and enhanced tumor growth in wild-type (WT) mice. Il9r−/− mice showed accelerated tumor growth, and administration of recombinant IL-9 (rIL-9) to tumor-bearing WT and Rag1−/− mice inhibited melanoma as well as lung carcinoma growth. Adoptive transfer of tumor-antigen–specific TH9 cells into both WT and Rag1−/− mice suppressed melanoma growth; this effect was abrogated by treatment with neutralizing antibodies to IL-9. Exogenous rIL-9 inhibited tumor growth in Rag1−/− mice but not in mast-cell–deficient mice, suggesting that the targets of IL-9 in this setting include mast cells but not T or B cells. In addition, we found higher numbers of TH9 cells in normal human skin and blood compared to metastatic lesions of subjects with progressive stage IV melanoma. These results suggest a role for IL-9 in tumor immunity and offer insight into potential therapeutic strategies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Primary accessions

Gene Expression Omnibus

References

  1. 1.

    et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

  2. 2.

    et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. published online doi:10.1056/NEJMoa1200690 (2 June 2012).

  3. 3.

    et al. CD4+ T cells eliminate MHC class II–negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96, 8633–8638 (1999).

  4. 4.

    et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109, 5346–5354 (2007).

  5. 5.

    et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637–650 (2010).

  6. 6.

    et al. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207, 651–667 (2010).

  7. 7.

    et al. Immunotherapy of cytotoxic T cell–resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med. 197, 387–393 (2003).

  8. 8.

    et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114, 1141–1149 (2009).

  9. 9.

    et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787–798 (2009).

  10. 10.

    et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362–373 (2008).

  11. 11.

    et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620–2627 (2003).

  12. 12.

    et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2–dependent angiogenesis. J. Immunol. 175, 6177–6189 (2005).

  13. 13.

    et al. IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J. Exp. Med. 206, 1457–1464 (2009).

  14. 14.

    , & Transcriptional regulation of Th17 cell differentiation. Semin. Immunol. 19, 409–417 (2007).

  15. 15.

    & Retinoid-related orphan receptors (RORs): roles in cellular differentiation and development. Adv. Dev. Biol. 16, 313–355 (2006).

  16. 16.

    et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 28, 29–39 (2008).

  17. 17.

    et al. Retinoid-related orphan receptor gamma controls immunoglobulin production and Th1/Th2 cytokine balance in the adaptive immune response to allergen. J. Immunol. 178, 3208–3218 (2007).

  18. 18.

    et al. Retinoid-related orphan receptor γ (RORγ) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc. Natl. Acad. Sci. USA 97, 10132–10137 (2000).

  19. 19.

    et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl. Acad. Sci. USA 106, 12885–12890 (2009).

  20. 20.

    et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-β and IL-4, and is inhibited by IFN-γ. J. Immunol. 153, 3989–3996 (1994).

  21. 21.

    et al. IL-4 inhibits TGF-β–induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3 effector T cells. Nat. Immunol. 9, 1347–1355 (2008).

  22. 22.

    , , , & Regulation of IL-9 expression by IL-25 signaling. Nat. Immunol. 11, 250–256 (2010).

  23. 23.

    et al. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol. Cell Biol. 88, 624–631 (2010).

  24. 24.

    et al. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188, 2357–2368 (1998).

  25. 25.

    & IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 22, 207–215 (2004).

  26. 26.

    et al. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am. J. Respir. Crit. Care Med. 183, 865–875 (2011).

  27. 27.

    et al. IL-9– and mast cell–mediated intestinal permeability predisposes to oral antigen hypersensitivity. J. Exp. Med. 205, 897–913 (2008).

  28. 28.

    et al. A critical role for mast cells and mast cell–derived IL-6 in TLR2-mediated inhibition of tumor growth. J. Immunol. 185, 7067–7076 (2010).

  29. 29.

    et al. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. Int. J. Cancer 125, 2912–2917 (2009).

  30. 30.

    , , , & Signals through 4–1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol. Immunother. 60, 1775–1787 (2011).

  31. 31.

    , , & High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6 (suppl. 1), S11–S14 (2000).

  32. 32.

    & Immune therapy for cancer. Annu. Rev. Immunol. 27, 83–117 (2009).

  33. 33.

    et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-γ. J. Immunol. 171, 608–615 (2003).

  34. 34.

    , & Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269–281 (2012).

  35. 35.

    et al. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol. Immunother. 60, 671–683 (2011).

  36. 36.

    & TH17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10, 248–256 (2010).

  37. 37.

    & Adoptive T cell therapy of cancer. Curr. Opin. Immunol. 21, 187–189 (2009).

  38. 38.

    & Adoptive immunotherapy of cancer using CD4+ T cells. Curr. Opin. Immunol. 21, 200–208 (2009).

  39. 39.

    et al. IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J. Immunol. 178, 3244–3251 (2007).

  40. 40.

    et al. Resident memory T cells (TRM) are abundant in human lung: diversity, function, and antigen specificity. PLoS ONE 6, e16245 (2011).

  41. 41.

    et al. A novel method for the isolation of skin resident T cells from normal and diseased human skin. J. Invest. Dermatol. 126, 1059–1070 (2006).

  42. 42.

    et al. Injury-induced GR-1+ macrophage expansion and activation occurs independently of CD4 T-cell influence. Shock 36, 162–169 (2011).

Download references

Acknowledgements

This research was supported by grants from US National Institutes of Health to T.S.K. (R01 AI-041707, R01 AI-097128 and P50 CA-093683), R.A.C. (R01-AR-056720 and R03-MH-095529) and A.M.J. (Z01-ES-101586). R.P. received a Research Grant Award from The Skin Cancer Foundation. The authors thank K. Gerrish (US National Institutes of Health) with his help with the microarray analysis. J.-C. Renauld39 (Ludwig Institute, Belgium) provided Il9r−/− mice and the corresponding control mice (Il9r+/−). Neutralizing antibodies to IL-9 (MM9C1) were a kind gift from J.v. Snick (Ludwig Institute, Belgium). Salary support for C.S. was provided by the Swiss National Science Foundation and the Foundation Rene Touraine and for R.A.C. from a Damon Runyon Clinical Investigator Award.

Author information

Affiliations

  1. Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

    • Rahul Purwar
    • , Christoph Schlapbach
    • , Xiaodong Jiang
    • , Robert C Fuhlbrigge
    • , Rachael A Clark
    •  & Thomas S Kupper
  2. Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

    • Sheng Xiao
    • , Wassim Elyaman
    • , Samia J Khoury
    •  & Vijay K Kuchroo
  3. Cell Biology Section, National Institute of Environmental Health Science, National Institutes of Health, Research Triangle Park, North Carolina, USA.

    • Hong Soon Kang
    •  & Anton M Jetten

Authors

  1. Search for Rahul Purwar in:

  2. Search for Christoph Schlapbach in:

  3. Search for Sheng Xiao in:

  4. Search for Hong Soon Kang in:

  5. Search for Wassim Elyaman in:

  6. Search for Xiaodong Jiang in:

  7. Search for Anton M Jetten in:

  8. Search for Samia J Khoury in:

  9. Search for Robert C Fuhlbrigge in:

  10. Search for Vijay K Kuchroo in:

  11. Search for Rachael A Clark in:

  12. Search for Thomas S Kupper in:

Contributions

R.P. designed the study, performed and analyzed the experiments, and wrote the manuscript. S.X. and H.S.K. performed experiments. W.E., A.M.J., S.J.K. and V.K.K. discussed the data, provided reagents and edited the manuscript. X.J. provided reagents. C.S., R.A.C. and R.C.F. performed the human T cell experiments, discussed the data and edited the manuscript. T.S.K. designed the study, analyzed the experiments and wrote the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Thomas S Kupper.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–6

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.2856

Further reading